SER (Serina Therapeutics) Return-on-Tangible-Asset: -161.12% (As of Mar. 2026)


SER Serina Therapeutics Inc SER
12 GF Score
Price $1.90
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Return-on-Tangible-Asset?

Serina Therapeutics SER -1.04% 12 Return-on-Tangible-Asset is -161.12% as of Mar. 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,413 Biotechnology companies, Serina Therapeutics ranks worse than 89.74% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Serina Therapeutics's annualized Net Income for the quarter that ended in Mar. 2026 was $-27.59 Mil. Serina Therapeutics's average total tangible assets for the quarter that ended in Mar. 2026 was $17.13 Mil. Therefore, Serina Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -161.12%.

The historical rank and industry rank for Serina Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:

SER' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -280.54   Med: -142   Max: 107.25
Current: -170.59

During the past 5 years, Serina Therapeutics's highest Return-on-Tangible-Asset was 107.25%. The lowest was -280.54%. And the median was -142.00%.

SER's Return-on-Tangible-Asset is ranked worse than
89.74% of 1413 companies
in the Biotechnology industry
Industry Median: -35.57 vs SER: -170.59

Serina Therapeutics  (AMEX:SER) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Serina Therapeutics Return-on-Tangible-Asset Related Terms


Serina Therapeutics Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Return-on-Tangible-Asset Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
-68.60 -198.52 107.25 -142.00 -280.54

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -286.17 -329.15 -171.77 -137.82 -161.12

SER vs NRSN, IGC, PVCT: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Serina Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Return-on-Tangible-Asset falls into.


SER
12GF Score
Serina Therapeutics Inc SER
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Return-on-Tangible-Asset Calculation

Serina Therapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-19.182/( (6.724+6.951)/ 2 )
=-19.182/6.8375
=-280.54 %

Serina Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-27.592/( (6.951+27.299)/ 2 )
=-27.592/17.125
=-161.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data.

What does a Return-on-Tangible-Asset of -161.12% mean?
Serina Therapeutics (SER) has a Return-on-Tangible-Asset of -161.12% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #1268 out of 1413 companies in the Biotechnology industry, placing it in the top 89.7%.
Is Serina Therapeutics' Return-on-Tangible-Asset too high?
Serina Therapeutics' current Return-on-Tangible-Asset is -161.12%. Based on the distribution chart, Serina Therapeutics ranks #1268 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Return-on-Tangible-Asset compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #1268 out of 1413 companies for Return-on-Tangible-Asset. This places Serina Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current Return-on-Tangible-Asset is -161.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current Return-on-Tangible-Asset of -161.12%. The current Return-on-Tangible-Asset is -161.12%. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Serina Therapeutics (SER), the current Return-on-Tangible-Asset is -161.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price